AnaptysBio Inc. (ANAB)
ANAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$45.59
-0.98% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$234.6M
+157.0% on 2024
Net income · 2025
-$13.2M
-5.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ANAB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001370053 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $234.6M |
| Net income | -$13.2M |
| Operating income | $226.9M |
| Net margin | -5.6% |
| Operating margin | 96.7% |
| Revenue growth | +157.0% |
| Cash | $138.2M |
| Total assets | $364.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-11-15 |
| Latest annual report | 10-KT | 2026-09-21 |
| Latest quarterly / interim | 10-Q | 2026-05-12 |
| Latest current report | 8-K | 2026-09-21 |
| Latest proxy | DEFA14A | 2026-06-29 |
Source: SEC EDGAR submissions feed, 725 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | -14.8% |
| 3 months | -14.0% |
| Year to date | +44.1% |
| 1 year | +115.2% |
| From 52-week high | -33.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OMER | Omeros Corporation | $18.88 | -3.82% | $1.4B |
| RAPP | Rapport Therapeutics Inc. | $28.99 | -3.85% | $1.4B |
| KLRA | Kailera Therapeutics Inc. | $10.77 | -4.94% | $1.4B |
| AAPG | Ascentage Pharma Group International American Depository Shares | $15.06 | -1.63% | $1.4B |
| NKTR | Nektar Therapeutics | $37.92 | -4.82% | $1.3B |
| GHRS | GH Research PLC | $18.85 | -5.84% | $1.3B |
| TYRA | Tyra Biosciences Inc. | $18.56 | -5.31% | $1.3B |
| KRSA | Korsana Biosciences Inc. | $31.66 | -6.99% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier